We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
EIP Pharma Inc. is a clinical-stage biopharmaceutical company focused on the development & commercialization of innovative drug treatments for Alzheimer’s disease (AD) and other central neurologic disorders. Our lead product candidate, neflamapimod, is a novel oral small molecule drug that inhibits the intra-cellular enzyme p38 mitogen-activated protein kinase alpha. The company was launched in 2014 by industry R&D leaders and has assembled a highly experienced executive management team, board of directors and scientific advisory board to execute on its mission.
Based on positive preclinical and phase 2a clinical trial results, in March 2018 the company initiated a Phase 2b randomized double-blind placebo-controlled clinical study of neflamapimod in subjects with early AD, which is called REVERSE-SD; the results of which are expected in the second half of 2019. The REVERSE-SD study is fully funded through a $20.5M Series B financing round completed in April 2018.